Summary
The company is shifting from a mainly API-led pharma business toward a differentiated platform built around complex formulations, specialty CDMO, peptides, oncology APIs, biologics, ADC capabilities and novel drug delivery systems.
The most important sustainability point: management explicitly said the current ~30% EBITDA margin is on the better side but they expect margins to remain in a similar range, preferring to be conservative and overdeliver.
Quarter Snapshot
| Metric | Q1 FY27 / Jun 2026 | Context |
|---|---|---|
| Sales / revenue | ₹466 Cr on Screener; ₹469 Cr in investor presentation | Up ~43-45% YoY |
| Operating profit | ₹136 Cr | Up from ₹91 Cr in Jun 2025 |
| OPM | 29% | Expanded from 28% in Jun 2025 and sustained above recent quarters |
| EBITDA | ₹139 Cr | Presentation says +42% YoY |
| Net profit | ₹101 Cr | Up ~115% YoY from ₹47 Cr |
| Other income | ₹9 Cr | Not the main driver of profit growth |
Why The Quarter Was Strong
- Broad-based vertical performance: Management said improvement was visible across three key verticals: API, formulations and biologics.
- API/CDMO recovery: API division remains focused on CDMO, peptides and oncology. Specialty CDMO contributed meaningfully to API growth.
- Complex formulation pipeline: Products such as Rotigotine transdermal patch, Abraxane, Enzalutamide and Abiraterone are important near-term launch drivers.
- Biologics monetisation: Management says investments in biologics, CDMO, novel drug delivery and NBE are under monetisation.
- Operating leverage: The company said large reinvestment is mostly behind it and "the harvesting is ahead," meaning fixed assets and R&D capabilities are starting to support higher revenue and margin.
Catalysts
| Catalyst | What Changed | Why It Matters |
|---|---|---|
| OERIS approval | SEC approved OERIS, extended-release Ondansetron injection; India launch planned after final CDSCO marketing authorisation | First-of-its-kind supportive oncology product with patent protection in India until 2039 |
| Complex launches | Rotigotine patch approved in Europe and filed in the US; Abraxane, Enzalutamide and Abiraterone planned for FY28 | Complex products have fewer generic competitors and better gross-margin potential |
| CDMO funnel | More than 25 CDMO programs discussed by management, including early-stage programs | Even partial commercial conversion can create a sizable multi-year business |
| Biologics platform | Aflibercept clinical studies completed; biologics CDMO programs in progress | Can add a higher-margin growth leg beyond small molecule APIs |
| Peptide capacity | Large peptide manufacturing capacity in India targeted for commissioning by end-FY27 | Positions Shilpa for GLP-1 and peptide opportunity pools |
| Orion agreement | Shilpa Biologicals entered co-development and supply agreement with Orion Corporation, Finland | Shows external validation of biologics capabilities |
Reason For Margin Expansion
Structural Drivers
- Complex formulations with limited competition.
- Higher CDMO and specialty contribution.
- Biologics and NBE investments beginning to monetise.
- Operating leverage from already-built manufacturing and R&D assets.
Risks To Margin
- Raw material price inflation from global political disruption.
- Only partial pass-through of cost increases to customers.
- Launch timing and regulatory approval timing.
- US tariff and regulatory risks.
Management linked gross margins to complex products: Rotigotine patch, Abraxane, Nor-UDCA and 505(b)(2) style differentiated products. They also acknowledged raw material pressure, with only partial pass-through possible.
What Changed In Business And Revenue Mix
| Vertical | Q1 FY27 Revenue Contribution | Business Role |
|---|---|---|
| API and others | ~47% | Oncology, non-oncology, payloads/linkers, peptides, polymers, GLP-1 and CDMO |
| Formulations | ~42% | Tablets/capsules, injectables, oral dissolving films, transdermal patches and formulation CDMO |
| Biologics | ~11% | NBE, microbials, mammalian products, biologics CDMO and ADCs |
The change is qualitative as much as numerical: Shilpa is moving from selling ingredients toward developing first-in-class drugs, partnering with innovators, and manufacturing complex molecules. That mix usually deserves higher margins if execution is consistent.
What Management Is Saying
- Management called Q1 FY27 the best quarter in the company's history.
- They highlighted that three years ago the company was a debt-heavy API business; now net debt-to-EBITDA is around 1.3x, ROCE is double digit, and credit rating has improved to AA-.
- They said big bets in biologics, CDMO, novel drug delivery and NBE are still under monetisation.
- They said "the reinvesting is largely behind us" and "the harvesting is ahead." This is the core operating leverage claim.
- On margins, management said the company has shown consistent performance around 30% and expects margins to remain in a similar range, while preferring to be conservative and overdeliver.
One-Off Or Sustainable?
Why It Can Sustain
- Growth is spread across API, formulations and biologics.
- CDMO funnel is broad, with more than 25 programs mentioned.
- Complex launches can support premium margins.
- Balance sheet leverage has improved materially.
Why It May Not Fully Repeat
- High-margin launches are timing-sensitive.
- CDMO programs may take years to commercialise.
- Regulatory setbacks can delay monetisation.
- Recent FTF Pharma NCLT disclosure is a governance/financial risk to monitor.
Sector Outlook
Shilpa operates in pharmaceuticals, specialty formulations, APIs, CDMO, biologics and oncology-linked platforms. The Indian pharma backdrop remains strong: India is a cost-efficient global manufacturer with export strength, while the domestic pharma market is expected to grow materially through 2030.
The more relevant sub-sector tailwind is complex pharma and CDMO. Global innovators are outsourcing development and manufacturing of difficult molecules, peptides, biologics and oncology-linked products. India can benefit where companies have regulatory credibility, technical capability and commercial reliability.
Projection If Management Walks The Talk
Assumptions: revenue growth continues from complex launches and CDMO/biologics monetisation; EBITDA margin holds near 27-30%; other income does not drive the numbers; tax rate normalises over time.
| Period | Revenue Estimate | Expected OPM | Expected EBITDA Margin | EBITDA / Operating Profit Estimate | PAT Estimate | Expected EPS |
|---|---|---|---|---|---|---|
| Q2 FY27 | ₹470-500 Cr | 27-30% | 28-30% | ₹130-150 Cr | ₹85-105 Cr | ₹4.35-5.37 |
| Q3 FY27 | ₹490-530 Cr | 27-30% | 28-30% | ₹135-160 Cr | ₹90-110 Cr | ₹4.60-5.63 |
| Q4 FY27 | ₹510-560 Cr | 27-30% | 28-30% | ₹140-170 Cr | ₹95-120 Cr | ₹4.86-6.14 |
| Q1 FY28 | ₹525-585 Cr | 27-30% | 28-30% | ₹145-175 Cr | ₹100-125 Cr | ₹5.12-6.39 |
| Next 4Q Run-Rate Case | Range |
|---|---|
| Revenue | ₹2,000-2,175 Cr |
| Expected OPM | 27-30% |
| Expected EBITDA margin | 28-30% |
| EBITDA / operating profit | ₹550-655 Cr |
| PAT | ₹370-460 Cr |
| Expected EPS | ₹18.93-23.53 |
| Conservative PAT case | ₹300-360 Cr if margins normalise closer to 24-26% |
Expected EPS uses approximately 19.55 crore shares outstanding and assumes no material dilution.
Investor Watchlist
- Does revenue sustain above ₹470-500 Cr per quarter?
- Does EBITDA margin hold above 27% without help from one-offs?
- How quickly do Rotigotine, Abraxane, Enzalutamide and Abiraterone ramp?
- Does OERIS receive final marketing authorisation and launch as planned?
- Do CDMO programs move from early-stage work to commercial revenue?
- Does biologics monetisation accelerate without major capex slippage?
- What is the financial impact, if any, from FTF Pharma's NCLT process?
- Are there any regulatory observations, product recalls or tariff hits in the US business?
Sources Used
- Shilpa Medicare Q1 FY27 investor presentation filed with BSE.
- Shilpa Medicare Q1 FY27 earnings conference call transcript filed with BSE.
- Shilpa Medicare FY26 annual report filed with BSE.
- Shilpa Medicare OERIS approval press release filed with BSE.
- Shilpa Medicare FTF Pharma NCLT disclosure filed with BSE.
- Screener consolidated financial snapshot for Shilpa Medicare.
- IBEF Indian Pharmaceutical Industry and Medical Devices sector outlook references.